Related Experiment Videos
The human tumor stem cell assay revisited.
International Journal of Cell Cloning
|March 1, 1985
Summary
The human tumor stem cell assay (HTSCA) shows promise for predicting cancer drug response, with 60% accuracy for positive results. However, clinicians must consider its limitations, including specimen variability and assay challenges.
Area of Science:
- Oncology
- Cancer Biology
- Drug Discovery
Background:
- The human tumor stem cell assay (HTSCA) is an in vitro method using bilayer soft agar to culture human tumor specimens.
- This assay aims to predict drug sensitivity and enhance understanding of tumor biology.
Purpose of the Study:
- To evaluate the clinical usefulness of the HTSCA in predicting therapeutic response.
- To discuss the potential and limitations of the HTSCA for clinicians.
Main Methods:
- Culturing fresh human tumor specimens in a bilayer soft agar system.
- Correlating in vitro assay results with clinical responses to therapeutic agents.
Main Results:
- The HTSCA demonstrated 60% accuracy in predicting positive clinical responses.
- The assay showed 90% accuracy in predicting lack of response to therapies.
Conclusions:
- The HTSCA shows promising clinical utility for predicting cancer drug efficacy.
- Clinicians must be aware of assay limitations, including specimen heterogeneity, technical challenges, and result variability.